Keyword

CUDC-101

Description: An investigational anticancer compound that inhibits histone deacetylases and the EGFR and HER2 receptor tyrosine kinases.
Wikidata ID: wiki/Q27076925
OpenAlex ID: keywords/cudc-101
2019 · Daniela Tomaselli, Alessia Lucidi, et al. · Medicinal Research Reviews · 136
2020 · Amr K.A. Bass, Mona S. El-Zoghbi, et al. · European Journal of Medicinal Chemistry · 132
2021 · Özge Çolakoğlu Havare · International Journal of Quantum Chemistry · 125
2021 · Zhuolong Zhou, Kevin Van der Jeught, et al. · Nature Biomedical Engineering · 119
2022 · Bo Yuan, Xiaofang Zhao, et al. · Clinical and Translational Medicine · 85
2014 · Anil Rana, Jimi Marin Alex, et al. · Medicinal Chemistry Research · 60
2013 · Qingwei Zhang, Congcong Wen, et al. · Journal of Pharmaceutical and Biomedical Analysis · 47
2019 · Simone Moertl, Sarah Payer, et al. · International Journal of Molecular Sciences · 41
2018 · Meiying Ji, Zhenling Li, et al. · Europe PMC (PubMed Central) · 29
2012 · Seung-Yong Seo · Archives of Pharmacal Research · 28
2016 · Lisa Zhang, Myriem Boufraqech, et al. · Oncotarget · 23
2016 · Renato J. Oliveira-Silva, Ana Carolina de Carvalho, et al. · Recent Patents on Anti-Cancer Drug Discovery · 21
2020 · Ramesh Soundararajan, George Wang, et al. · Molecular Pharmaceutics · 20
Works count: 86
Citation count: 2,063
Year
Topic
Type